Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed375%
active_not_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_3

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

NCT03183245
completedphase_2

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

NCT02887859
completedphase_3

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

NCT02644941
active_not_recruitingphase_2

Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma

NCT03005418

Clinical Trials (4)

Showing 4 of 4 trials
NCT03183245Phase 3

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

Completed
NCT02887859Phase 2

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

Completed
NCT02644941Phase 3

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

Completed
NCT03005418Phase 2

Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4